AU2019239048B2 - Compositions - Google Patents

Compositions Download PDF

Info

Publication number
AU2019239048B2
AU2019239048B2 AU2019239048A AU2019239048A AU2019239048B2 AU 2019239048 B2 AU2019239048 B2 AU 2019239048B2 AU 2019239048 A AU2019239048 A AU 2019239048A AU 2019239048 A AU2019239048 A AU 2019239048A AU 2019239048 B2 AU2019239048 B2 AU 2019239048B2
Authority
AU
Australia
Prior art keywords
ala
ser
thr
leu
flagellin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019239048A
Other languages
English (en)
Other versions
AU2019239048A1 (en
Inventor
Philip COWIE
Emma Elizabeth Clare HENNESSY
Delphine Louise Claudette LAUTE-CALY
Imke Elisabeth MULDER
Emma RAFTIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Bioscience Inc
Original Assignee
CJ Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Application filed by CJ Bioscience Inc filed Critical CJ Bioscience Inc
Publication of AU2019239048A1 publication Critical patent/AU2019239048A1/en
Application granted granted Critical
Publication of AU2019239048B2 publication Critical patent/AU2019239048B2/en
Assigned to CJ BIOSCIENCE, INC. reassignment CJ BIOSCIENCE, INC. Request for Assignment Assignors: 4D PHARMA RESEARCH LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
AU2019239048A 2018-03-19 2019-03-19 Compositions Ceased AU2019239048B2 (en)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GB1804384.4 2018-03-19
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
EP18178350 2018-06-18
EP18178350.7 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
GB1809953.1 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GB1812378.6 2018-07-30
GB1813444.5 2018-08-17
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GB1813423.9 2018-08-17
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GB1816834.4 2018-10-16
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GB1901199.8 2019-01-29
GB1901218.6 2019-01-29
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GB1901992.6 2019-02-13
PCT/EP2019/056809 WO2019180000A1 (en) 2018-03-19 2019-03-19 Compositions

Publications (2)

Publication Number Publication Date
AU2019239048A1 AU2019239048A1 (en) 2020-11-05
AU2019239048B2 true AU2019239048B2 (en) 2022-07-21

Family

ID=65955185

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019239048A Ceased AU2019239048B2 (en) 2018-03-19 2019-03-19 Compositions
AU2019238358A Abandoned AU2019238358A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019238358A Abandoned AU2019238358A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Country Status (25)

Country Link
US (3) US11419931B2 (enExample)
EP (3) EP4046644A1 (enExample)
JP (3) JP2021518414A (enExample)
KR (2) KR102578117B1 (enExample)
CN (2) CN112004543A (enExample)
AU (2) AU2019239048B2 (enExample)
BR (2) BR112020019008A2 (enExample)
CA (2) CA3094297A1 (enExample)
CY (1) CY1125104T1 (enExample)
DK (1) DK3768284T3 (enExample)
ES (1) ES2908826T3 (enExample)
HR (1) HRP20220368T1 (enExample)
HU (1) HUE058151T2 (enExample)
IL (2) IL277422A (enExample)
LT (1) LT3768284T (enExample)
MA (1) MA52128A (enExample)
MD (1) MD3768284T2 (enExample)
MX (2) MX2020009733A (enExample)
PL (1) PL3768284T3 (enExample)
RS (1) RS63090B1 (enExample)
SG (2) SG11202009254YA (enExample)
SI (1) SI3768284T1 (enExample)
SM (1) SMT202200111T1 (enExample)
TW (2) TW202003001A (enExample)
WO (2) WO2019180051A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021113500A2 (en) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
KR102461645B1 (ko) * 2020-10-20 2022-11-01 전남대학교산학협력단 플라젤린 융합 단백질을 포함하는 비알코올성 지방간질환 또는 대사증후군 예방 또는 치료용 조성물
EP4384194A4 (en) * 2021-10-08 2025-07-16 Univ Iowa State Res Found Inc USE OF DOPAMINE-PRODUCING PRODUCTS TO INCREASE VACCINE EFFECTIVENESS
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (enExample) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121863A1 (en) * 2014-02-12 2015-08-20 Transalgae Israel Ltd. Algal based edible vaccines
WO2017085520A1 (en) * 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
EP2133092B1 (en) 2007-03-19 2015-12-09 Morishita Jintan Co., Ltd. Oral vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
EP2486134B1 (en) * 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
EP2731572B1 (en) 2011-07-13 2021-04-07 Pharmaxis Ltd. Improvements relating to delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
WO2014043593A2 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
BR112020002212A2 (pt) 2017-08-10 2020-07-28 4D Pharma Research Limited composições compreendendo cepas bacterianas
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121863A1 (en) * 2014-02-12 2015-08-20 Transalgae Israel Ltd. Algal based edible vaccines
WO2017085520A1 (en) * 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LORENA ROMÁN ET AL: JOURNAL OF APPLIED ANIMAL RESEARCH, vol. 43, no. 2, 18 July 2014 (2014-07-18), IN, pages 177 - 183 *

Also Published As

Publication number Publication date
US20210138058A1 (en) 2021-05-13
EP3768285A1 (en) 2021-01-27
JP2021518414A (ja) 2021-08-02
RS63090B1 (sr) 2022-04-29
JP2023100747A (ja) 2023-07-19
US20210169950A1 (en) 2021-06-10
JP2021518129A (ja) 2021-08-02
WO2019180000A1 (en) 2019-09-26
MA52128A (fr) 2021-01-27
SG11202009254YA (en) 2020-10-29
WO2019180051A1 (en) 2019-09-26
PL3768284T3 (pl) 2022-04-11
AU2019239048A1 (en) 2020-11-05
SMT202200111T1 (it) 2022-05-12
CY1125104T1 (el) 2024-02-16
ES2908826T3 (es) 2022-05-04
IL277421A (en) 2020-11-30
CN111886018A (zh) 2020-11-03
MX2020009733A (es) 2022-10-27
IL277421B (en) 2022-04-01
MD3768284T2 (ro) 2022-06-30
US11419931B2 (en) 2022-08-23
EP4046644A1 (en) 2022-08-24
CA3094297A1 (en) 2019-09-26
EP3768284B1 (en) 2022-01-05
SI3768284T1 (sl) 2022-04-29
DK3768284T3 (da) 2022-03-07
CA3094139A1 (en) 2019-09-26
BR112020019008A2 (pt) 2020-12-29
AU2019238358A1 (en) 2020-10-08
US11857614B2 (en) 2024-01-02
MX2020009736A (es) 2021-01-08
TW202003000A (zh) 2020-01-16
SG11202009259VA (en) 2020-10-29
US20220257745A1 (en) 2022-08-18
HUE058151T2 (hu) 2022-07-28
KR102578117B1 (ko) 2023-09-12
CN112004543A (zh) 2020-11-27
BR112020018818A2 (pt) 2021-05-04
KR20210003096A (ko) 2021-01-11
HRP20220368T1 (hr) 2022-06-24
LT3768284T (lt) 2022-04-11
TW202003001A (zh) 2020-01-16
EP3768284A1 (en) 2021-01-27
IL277422A (en) 2020-11-30
KR20200134255A (ko) 2020-12-01

Similar Documents

Publication Publication Date Title
US11857614B2 (en) Enterococcus gallinarum flagellin polypeptides
KR20180096591A (ko) 광범위 인플루엔자 바이러스 백신
TW201930340A (zh) 新抗原及其用途
JP6786074B2 (ja) エキソソーム標的ｄｎａワクチン
KR102823291B1 (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
US12364743B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
EA024826B1 (ru) Способ лечения латентного туберкулеза
US12472245B2 (en) Compositions and methods
JP2021521798A (ja) がんに対する組換え型の治療介入
EP4045150B1 (en) Immunogenic compounds for treatment of adrenal cancer
CN114746112A (zh) 用于预防和治疗b细胞恶性肿瘤的抗原肽
US11478538B2 (en) Immunogenic compounds for cancer therapy
CN110214028A (zh) 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
HK40043598B (en) Compositions of entrecoccus flagellin for use in therapy
HK40043598A (en) Compositions of entrecoccus flagellin for use in therapy
OA20217A (en) Compositions.
EP4424700A1 (en) Novel peptide targeting dendritic cells, and composition for treating cancer comprising same
WO2023200865A2 (en) Cancer therapy
WO2024233406A2 (en) Cpmv-rna immunotherapy
JP2024054375A (ja) エキソソーム標的ｄｎａワクチン
WO2024075067A1 (en) Cancer vaccine composition that comprises a host cell expressing glypican-1 (gpc-1)
WO2018091142A1 (en) Cyaa polypeptides as immune enhancer
EP3541412A1 (en) Cyaa polypeptides as immune enhancer
Mahbuba Generation and evaluation of SMT-expressing Lactococcus lactis live vaccines against visceral leishmaniasis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CJ BIOSCIENCE, INC.

Free format text: FORMER OWNER(S): 4D PHARMA RESEARCH LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired